Get the Stockscreener App
101.73
0.14%
0.125
Exact Sciences Corp stock is traded at $101.73, with a volume of 3.06M.
It is up +0.14% in the last 24 hours and up +0.69% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$101.61
Open:
$101.57
24h Volume:
3.06M
Relative Volume:
0.60
Market Cap:
$19.31B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-18.46
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
-0.14%
1M Performance:
+0.69%
6M Performance:
+90.69%
1Y Performance:
+76.04%
1-Day Range:
$101.55
$101.84
1-Week Range:
$101.51
$102.05
52-Week Range:
$38.81
$102.66
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.73 | 19.28B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
622.22 | 229.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.50 | 166.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
706.38 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.21 | 40.52B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
240.65 | 39.95B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Assessing Exact Sciences (EXAS) Valuation After A Strong Momentum-Driven Share Price Run - simplywall.st
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group - GuruFocus
Abbott bets on cancer screening with $23 billion Exact Sciences deal - MSN
Pharma News: Can Exact Sciences Corporation EXK stock retain market dominanceVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
1 High-Flying Stock on Our Watchlist and 2 We Question - Finviz
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap? - AD HOC NEWS
19,260 Shares in Exact Sciences Corporation $EXAS Purchased by Strait & Sound Wealth Management LLC - MarketBeat
Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer - AD HOC NEWS
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
Alert from law firm on Exact Sciences-Abbott deal withdrawn - marketscreener.com
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie ... - Bluefield Daily Telegraph
Should You Continue to Hold EXAS Stock in Your Portfolio Now? - Yahoo Finance
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook - AD HOC NEWS
Exact Sciences Corp. Stock Tests Investor Patience as Diagnostics Story Enters a New Act - AD HOC NEWS
Exact Sciences accelerates executive bonuses and equity awards ahead of merger By Investing.com - Investing.com Australia
Exact Sciences accelerates executive bonuses and equity awards ahead of merger - Investing.com Nigeria
Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts - MarketBeat
What Are the Top 20 Gastroenterology Companies in 2025? - Global Growth Insights
Is Exact Sciences Stock Still Attractive After a 78.1% Surge in 2025? - simplywall.st
How The Abbott Takeover Is Rewriting Exact Sciences Story And Valuation - Yahoo Finance
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
Is Exact Sciences (EXAS) Still Undervalued After Its Recent Share Price Surge? - simplywall.st
Holocene Advisors LP Acquires 1,404,086 Shares of Exact Sciences Corporation $EXAS - MarketBeat
EXAS Quantitative Stock Analysis - Nasdaq
Why Exact Sciences Stock Surged Today - AOL.com
Exact Sciences Corporation $EXAS Shares Sold by Bellevue Group AG - MarketBeat
Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer - MSN
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS - The AI Journal
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect - Business Wire
Quantbot Technologies LP Invests $604,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (NASDAQ:EXAS) Sets New 52-Week HighTime to Buy? - MarketBeat
Exact Sciences stock reaches 52-week high at 101.89 USD By Investing.com - Investing.com South Africa
Exact Sciences stock reaches 52-week high at 101.89 USD - Investing.com
Exact Sciences Showcases Breadth of Early Detection and Treatmen - GuruFocus
Peninsula company rides blank check to Wall Street after raising more than $1 billion as a startup - The Business Journals
Baird Financial Group Inc. Sells 30,218 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Assessing Exact Sciences After 77.5% YTD Surge and Abbott Deal Outlook - Yahoo Finance
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Cancer detection firm Freenome to go public via $330 million SPAC deal - statnews.com
Cancer blood test maker Freenome going public with $330M SPAC - BioWorld MedTech
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
Has Exact Sciences Rally of Over 50% Left Room for Further Upside? - simplywall.st
OMERS ADMINISTRATION Corp Sells 113,387 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Published on: 2025-12-04 02:35:05 - Newser
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? - Yahoo Finance
Schroder Investment Management Group Raises Stock Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences (NASDAQ:EXAS) Sees Large Volume IncreaseHere's Why - MarketBeat
Top 2 Health Care Stocks You May Want To Dump This Month - Benzinga
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exact Sciences Corp Stock (EXAS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Dec 23 '25 |
Option Exercise |
0.00 |
73,080 |
0 |
66,487 |
| Condella Sarah | EVP, Human Resources |
Dec 23 '25 |
Option Exercise |
0.00 |
47,208 |
0 |
118,059 |
| Herriott James | SVP, General Counsel & Sec |
Dec 23 '25 |
Option Exercise |
0.00 |
33,780 |
0 |
32,934 |
| Bloomer Aaron | EVP, Chief Financial Officer |
Dec 23 '25 |
Option Exercise |
0.00 |
63,099 |
0 |
59,571 |
| ORVILLE JACOB A | EVP, GM, Screening |
Nov 19 '25 |
Sale |
75.00 |
5,000 |
375,000 |
23,237 |
| Herriott James | SVP, General Counsel & Sec |
Nov 19 '25 |
Sale |
70.00 |
1,000 |
70,000 |
11,585 |
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):